Answers are grounded in this paper and cite their sources.
Sunitinib is active in recurrent atypical/malignant meningioma patients. A randomized trial should be performed.
No takes yet. Share an insight, caveat, or question.
Kaley et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: